Bryan Bennett
About Bryan Bennett
Bryan Bennett is the WWHEOR PRO Lead at Bristol-Myers Squibb in Uxbridge, with over 15 years of experience in clinical outcome assessments across various sectors.
Current Role at Bristol-Myers Squibb
Bryan Bennett is currently working at Bristol-Myers Squibb as the WWHEOR PRO Lead in Uxbridge. In this role, he is responsible for leading initiatives related to health economics and outcomes research (HEOR) and patient-reported outcomes (PRO) on a global scale.
Professional Experience at Adelphi Values
From 2014 to 2018, Bryan Bennett worked as the Director of Patient Centered Outcomes at Adelphi Values in Bollington near Manchester. During his tenure, he oversaw projects focused on patient-centered research and clinical outcome assessments. His role included managing a team and directing research activities aimed at capturing patient experiences and outcomes effectively.
Experience at AstraZeneca
Bryan served as a PRO Senior Scientist at AstraZeneca from 2013 to 2014 for nine months. Based in Alderley Edge and London, he contributed to the development of patient-reported outcomes within clinical trials, ensuring that patient perspectives were accurately captured and reflected in the clinical evidence.
Educational Background and PhD from Bangor University
Bryan Bennett completed his PhD in Psychology at Bangor University from 2005 to 2009. His doctoral studies equipped him with in-depth knowledge and research skills in the field of psychology. Prior to this, he obtained a BSc (Hons) in Psychology from Glasgow Caledonian University, graduating with first-class honors in 2002.
Clinical and Research Experience
Bryan has over 15 years of experience in clinical outcome assessments (COA) across various sectors, including academia, clinical practice, consultancy, and the pharmaceutical industry. His work spans multiple therapeutic areas such as oncology, immunological disorders, rheumatology, gastrointestinal disorders, adult mental health, and neuropsychology. He has been involved in dossier development for regulatory approvals, preparing briefing documents for the FDA and EMA, and attending scientific advice meetings to discuss PRO endpoints in clinical trials.